Dr Lizanne NilewskiSenior Scientist at Denali TherapeuticsSpeaker
Profile
Dr. Lizanne Nilewski is a Senior Scientist in the Oligonucleotide Therapeutics group at Denali Therapeutics working on BBB delivery of various classes of therapeutics with a current focus on oligonucleotide-based drugs applied to neurodegenerative disorders. Joining Denali in 2019, Lizanne was trained as a small molecule medicinal chemist and worked on various CNS targets before also collaborating with the TfR-enabled transport vehicle team to work on oligonucleotide chemistry and optimization of ASO and siRNA conjugates. For the past five years she has worked on antibody-oligo conjugates for brain delivery, including DNL628 which is a MAPT-targeting ASO-TV conjugate currently in Phase 1b trials.
Agenda Sessions
Bridging the Divide: Leveraging the Transport Vehicle Platform to Deliver Enzyme, Antibody, and Oligonucleotide-based Therapeutics across the BBB
, 11:45amView Session